Atlas Two · The Pathogen Atlas

Every threat. Every microbe. Modeled the same way.

Every virus, bacterium, fungus, parasite, prion, and commensal that touches human biology — catalogued at the same depth as the host.

A vaccine is a designed interface between a host and a pathogen. To build that interface in hours, both sides need to be modeled end-to-end. Held to one standard: structure, mechanism of harm, immune signature, and mutation pressure.

2Entries
6Classes
For Everyone
0Paywalls
The Classes

Six categories. Every microbe that touches human biology.

The same systematic approach for each — structure, mechanism of harm, immune signature, mutation pressure. The scale ladder, viewed from the other side of the encounter.

Viruses

Influenza, coronaviruses, HIV, herpes, ebola — fast mutation; highest-priority threat class.

Bacteria

TB, staph, strep, mycobacteria — antibiotic resistance and cell-cell warfare with the immune system.

Fungi

Candida, aspergillus, cryptococcus — emerging threats with few available drug classes.

Parasites

Plasmodium, helminths, trypanosomes — global disease burden; complex life cycles.

Prions

CJD, kuru — misfolded protein aggregates that stress-test every assumption in the model.

Microbiome

Gut, skin, respiratory commensals — not every microbe is a threat; many are partners.

Class 01

Viruses

The fastest-evolving category. Viruses hijack host cellular machinery and mutate at rates that outpace immune memory — making them the highest-priority target for the human model. Two entries currently filled, both cardiovascular.

Picornaviridae · Enterovirus B · +ssRNA, Non-enveloped · ~28–30 nm

Coxsackievirus B

Non-enveloped positive-sense single-stranded RNA enterovirus with six serotypes (B1–B6). The leading infectious cause of acute myocarditis in the developed world and a major antecedent of dilated cardiomyopathy. Enters cardiomyocytes via the coxsackievirus-adenovirus receptor (CAR) concentrated at intercalated discs; destroys them by direct cytolysis and protease 2A­-mediated cleavage of dystrophin.

Structure

CapsidT=1 icosahedral, 60 protomers; VP1, VP2, VP3 (surface), VP4 (internal, stabilising)
Genome~7.4 kb +ssRNA; single ORF flanked by 5′/3′ UTRs; VPg protein at 5′ end; IRES-driven, cap-independent translation
Entry receptorCAR (Coxsackievirus-Adenovirus Receptor) — concentrated at cardiac intercalated discs; CD55 (decay-accelerating factor) acts as attachment co-receptor
StabilityStable at low pH (gut transit); thermolabile above 50 °C; transmitted fecal-oral and respiratory
SerotypesB1–B6; B3 and B5 most commonly linked to myocarditis; B4 associated with pancreatitis

Mechanisms of Harm

Direct cytolytic replication

CVB enters cardiomyocytes via CAR at intercalated discs — the same junctions mediating electrical coupling — facilitating spread across the myocardial syncytium. Viral protease 3Cpro and RdRp (3Dpol) drive replication in membrane-associated complexes. Progeny virions accumulate until lytic release destroys the cell.

Protease 2A cleavage of dystrophin

Viral protease 2Apro cleaves human dystrophin at the hinge-3 domain, severing the cytoskeleton–sarcolemma link. This increases Ca²⁺ sarcolemmal permeability, initiates a necrotic cascade independent of cytolysis, and creates a phenotype mechanistically similar to Duchenne muscular dystrophy — explaining why DCM can persist long after viral clearance.

Immune-mediated injury & autoimmunity

CD8⁺ cytotoxic T lymphocytes target infected cardiomyocytes in the adaptive phase. Molecular mimicry between CVB VP1 capsid proteins and cardiac myosin heavy chain (MHC-α, MHC-β) generates autoreactive T cells and anti-cardiac myosin antibodies that continue damaging the myocardium after viral clearance — the autoimmune mechanism of post-viral DCM (~30% of severe cases).

Cardiac Pathology

PhaseMechanismTissue signature
Acute (days 1–14)Direct cytolysis, innate inflammationCardiomyocyte necrosis, neutrophil/macrophage infiltrate, oedema
Subacute (weeks 2–8)CD8⁺ T-cell cytotoxicity, immune-complex depositionLymphocytic infiltrate (Dallas criteria), ongoing myocyte death
Chronic / healedScar formation or ongoing autoimmune activationInterstitial fibrosis, ventricular remodelling, chamber dilation — DCM in ~30% of severe cases

Immune Signature

IFN-α/β (type I interferons) RIG-I / MDA5 RNA sensors NK cells & macrophages CD4⁺ Th1 CD8⁺ CTL (primary effector) Anti-cardiac myosin Ab (30–50% of DCM post-myocarditis) Autoreactive T cells (molecular mimicry)

References

Coronaviridae · Betacoronavirus · +ssRNA, Enveloped · 80–120 nm

SARS-CoV-2 (cardiac effects)

Betacoronavirus responsible for COVID-19. This entry focuses on cardiac interactions: ACE2-dependent entry into cardiomyocytes, direct viral myocarditis, cytokine-storm-mediated myocardial injury, microvascular thrombosis and endotheliopathy, arrhythmias, and right ventricular failure. ACE2 — the primary receptor — is expressed on cardiomyocytes, endothelial cells, and pericytes, making the heart directly accessible to the virus.

Structure — Key Cardiac-Relevant Proteins

Spike (S)Binds ACE2 (S1 domain); mediates membrane fusion (S2); primed by TMPRSS2. ACE2 is expressed on cardiomyocytes, endothelial cells, and pericytes — the molecular basis for cardiac tropism.
NSP12 (RdRp)Genome replication polymerase; target of remdesivir.
M (membrane)Structural; suppresses IFN-β induction — key immune evasion mechanism during early infection.
N (nucleocapsid)RNA packaging and replication complex scaffold; primary diagnostic antigen.
Genome~30 kb +ssRNA; largest RNA viral genome; 16 non-structural proteins (NSP1–16) plus 4 structural (S, E, M, N).

Mechanisms of Cardiac Injury

1 · Direct viral myocarditis

SARS-CoV-2 spike binds ACE2 on cardiomyocytes. Direct infection confirmed in autopsy specimens by in situ hybridisation for viral RNA and electron microscopy. Causes both viral cytolysis and immune-cell-mediated myocyte killing, paralleling CVB myocarditis. Clinical presentation ranges from asymptomatic troponin rise to fulminant myocarditis.

2 · ACE2 downregulation → RAAS imbalance

Spike binding internalises ACE2, reducing surface expression and shifting local RAAS toward excess angiotensin II (vasoconstrictive, pro-inflammatory, pro-fibrotic). This promotes cardiomyocyte inflammation, oxidative stress, and fibrosis independent of direct viral replication.

3 · Cytokine storm (immune-mediated injury)

Severe COVID-19 triggers systemic hyperinflammation: markedly elevated IL-6, IL-1β, TNF-α, and ferritin. Myocardial inflammation in this context is partly a bystander effect of systemic cytokines — macrophage activation syndrome (MAS)-like phenotypes described in fatal cases with prominent cardiac involvement.

4 · Endotheliopathy and microvascular thrombosis

SARS-CoV-2 activates endothelium; elevates D-dimer, fibrinogen, and von Willebrand factor; induces platelet hyperactivation. Creates conditions for: coronary microvascular thrombosis (type 2 MI), acute plaque rupture (type 1 MI in patients with pre-existing atherosclerosis), and pulmonary embolism leading to right ventricular pressure overload.

5 · Arrhythmias

QTc prolongation, atrial fibrillation, and ventricular arrhythmias common in hospitalised patients. Mechanisms: myocardial inflammation disrupts conduction; electrolyte derangements; hypoxia; catecholamine surge; direct viral effects on ion-channel expression (including Nav1.5, hERG).

Cardiac Pathology — Frequency in Hospitalised Patients

SyndromeFrequencyPrimary mechanism
Troponin elevation (asymptomatic)20–30%Demand ischaemia, microvascular injury, subclinical myocarditis
Acute myocarditis (clinical)1–5%Direct viral + immune-mediated
Type 1 MI~2–4%Plaque rupture in inflammatory context
Type 2 MI~5–10%Demand-supply mismatch, microvascular thrombosis
Arrhythmia (any)5–20%Multi-factorial (see above)
Right ventricular failureUncommon; high mortalityPulmonary hypertension, PE, high-PEEP ventilation

Immune Signature

RIG-I / MDA5 (blunted by M protein) IL-6 ↑↑ IL-1β ↑ TNF-α ↑ Ferritin ↑↑ (MAS-like) CD4⁺ Th1 / Th17 CD8⁺ CTL (exhausted in severe disease) Autoantibodies (subset; implicated in Long COVID)

References

  • Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2. Cell. 2020;181(2):271–280. doi:10.1016/j.cell.2020.02.052 · PubMed 32142651
  • Lindner D, Fitzek A, Brauninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5(11):1281–5. doi:10.1001/jamacardio.2020.3551 · PubMed 32730555
  • Giustino G, Croft LB, Stefanini GG, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2043–55. doi:10.1016/j.jacc.2020.08.069 · PubMed 33121713
  • Eiros R, Barreiro-Perez M, Martin-Garcia A, et al. Pericarditis and myocarditis long after SARS-CoV-2 infection. medRxiv. 2020. doi:10.1101/2020.07.12.20151316

Viruses — Additional Entries

Antigenic drift/shift; neuraminidase inhibitors; 290–650K deaths/year 38M PLHIV; ART suppresses to undetectable; CCR5Δ32 natural resistance 296M chronic; 820K deaths/year; 95% vaccine efficacy 58M chronic; 95%+ cure with DAAs; 290K deaths/year One of most infectious pathogens; 95%+ vaccine efficacy (MMR) 390M infections/year; NS1/ADE mechanism; Dengvaxia only in seropositive Primary varicella; reactivation as herpes zoster; Shingrix 97% efficacy EBV+ in 95% adults; EBV→MS causal; oncogenesis (Burkitt, NPC, PTLD) E6 → p53 degradation; E7 → Rb inactivation; Gardasil-9 prevents 90% HPV cancers Leading cause of bronchiolitis; Abrysvo/mRESVIA vaccines approved 2023 685M cases/year; #1 foodborne illness globally; no vaccine available 128K deaths/year in children <5; vaccine-preventable (Rotarix, RotaTeq) ~100% CFR once symptomatic; 59K deaths/year; PEP nearly 100% effective Microcephaly (congenital); GBS (post-infection); no approved vaccine 25–90% CFR; DIC/vascular leak; Ervebo (rVSV-ZEBOV) licensed 2019

Bacteria

10M new cases/year; #1 infectious disease killer; LTBI in 25% of humanity MRSA; toxic shock syndrome; biofilm; ~120K bacteraemias/year (US) HUS in children (O157:H7); UTI #1 cause; ESBL/carbapenem resistance Leading cause of bacterial pneumonia/meningitis; PCV13/PCV20 vaccines Spastic paralysis; ~209K deaths/year; 100% preventable by tetanus toxoid 50% of humanity colonized; Correa cascade → gastric cancer; MALT lymphoma ARF; post-streptococcal GN; necrotizing fasciitis; 500K deaths/year 500K cases/year (US); FMT 80–90% recurrence cure; NLRP3 activation Bacterial meningitis; waterhouse-friderichsen; MenACWY/Bexsero vaccines Foodborne; BBB/placental crossing; intracellular actin propulsion; high CFR 11M typhoid cases/year; typhoid toxin; TCV vaccine 80% efficacy

Fungi

#1 fungal ICU pathogen; fluconazole/echinocandin; SCFA-Treg immunomodulation Invasive aspergillosis 90% mortality if untreated; voriconazole first-line ~180K deaths/year; AIDS meningitis; L-AmB + 5-FC induction PCP in AIDS/immunosuppressed; TMP-SMX prophylaxis/treatment

Parasites

247M cases/year; 619K deaths; R21/Matrix-M 77% efficacy ~33% humans seropositive; congenital toxoplasmosis; AIDS reactivation 200M infections/year; most common intestinal parasite worldwide HAT Stage 1→2 CNS invasion; fexinidazole oral treatment; ~990 cases 2023 6-7M infected; 30% develop cardiomyopathy; apical aneurysm / RBBB Kala-azar; 50–90K cases/year; 95%+ fatal if untreated; L-AmB treatment

Prions

Protein-only infectious agents — no nucleic acid genome. PrPSc misfolding nucleates conversion of normal PrPC, producing uniformly fatal transmissible spongiform encephalopathies. CJD, kuru, fatal familial insomnia — edge cases that stress-test every assumption about what constitutes an infectious agent.

~1–2/M/year sporadic CJD; 100% fatal; no approved treatment; 253 aa; no nucleic acid genome

Human Microbiome

Inversely correlated with T2DM/obesity; metformin correlation; pasteurized form approved (EU) Infant gut pioneer; B. infantis vs B. longum subspecies; Treg induction nBF: Treg-inducing commensal; ETBF: colonic carcinogen; CRC-linked ↓70% in Crohn's; anti-inflammatory postbiotics; butyrate colonocyte fuel LGG strain; Cochrane meta: acute diarrhea duration ↓ 1 day; IEC barrier

Help expand the Pathogen Atlas

Every entry follows the same schema: structured frontmatter, peer-reviewed citations, and cross-atlas links to the host biology and medicine atlases.